We retrospectively investigated outcomes of haploidentical donor (HID) transplant for adults with standard-risk acute lymphoblastic leukaemia (ALL) in first complete remission (CR1) compared with human leucocyte antigen (HLA)-matched sibling donor (MSD) and HLA-matched unrelated donor (MUD) transplants. A total of 348 adult patients were enrolled, including 127 HID, 144 MSD and 77 MUD recipients. The cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD) was 39Á5%, 24Á0% and 40Á3% for HID, MSD and MUD, respectively (P = 0Á020). However, there was no difference in grade III-IV aGVHD (11Á4%, 7Á7%, 13Á5%, respectively, P = 0Á468). The 5-year cumulative transplant-related mortality was 16Á4%, 11Á6% and 19Á6% (P = 0Á162), the 5-year relapse rate post-transplantation was 14Á8%, 21Á1% and 16Á7% (P = 0Á231), the 5-year overall survival was 70Á1%, 73Á7% and 69Á8% (P = 0Á525), and the 5-year disease-free survival was 68Á7%, 67Á3% and 63Á7%, respectively (P = 0Á606). Furthermore, the 3-year GVHD-free, relapse-free survival was not different (50Á8%, 54Á9% and 52Á2%, respectively, P = 0Á847). Our results indicate that the outcomes of HID transplants are equivalent to those of MSD and MUD, and that HID transplantation is a valid alternative for standard-risk adults with ALL in CR1 who lack matched donors.
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Allogeneic haematopoietic stem cell transplantation (allo-HSCT) has been regarded as a potential strategy for adult acute lymphoblastic leukaemia (ALL). A growing body of evidence has suggested that adults with ALL in the first complete remission (CR1) could benefit from allo-HSCT, particularly high-risk patients (Yanada et al, 2006; Gupta et al, 2013; Dhedin et al, 2015) . Therefore, the 2015 National Comprehensive Cancer Network (NCCN) Guidelines recommended that allo-HSCT could be used as front-line treatment for these patients (Alvarnas et al, 2015) . Some reports have suggested that the survival of human leucocyte antigen (HLA)-matched unrelated donor (MUD) transplants was equivalent to that of matched sibling donor (MSD) transplants for high-risk adults ALL in CR1 (Nishiwaki et al, 2010; Dhedin et al, 2015) . Other studies have demonstrated that haploidentical donor (HID) transplants are also beneficial for high-risk patients with ALL in CR1 (Chang et al, 2016a; Dufort et al, 2016; Wang et al, 2016) . Additionally, our recent randomized, multi-centre study has provided evidence that HID transplants have outcomes similar to those of MSD transplants for high-risk adults with ALL in CR1 . However, there have also been a few reports that HID transplants could provide benefit for standard-risk adult ALL patients in CR1 (Nishiwaki et al, 2013a; Mo et al, 2015; Sun et al, 2015) . In this report, we performed a retrospective study of standard-risk adults with ALL in CR1 who underwent HID, MSD or MUD transplants at our centres. Our results indicate that the outcomes for HID transplants are equivalent to those of MSD and MUD transplants.
Patients and methods

Study design and patients
This retrospective study examined consecutive patients at Nanfang Hospital, Peking University People's Hospital and Henan Cancer Hospital between February 2010 and December 2014. Patients with ALL fulfilling the following conditions were selected for analysis: (i) adults aged 16-60 years, (ii) diagnosis of ALL was confirmed by histological, immunophenotypic, cytogenetic and molecular review of the initial diagnostic bone marrow (BM) aspirate specimen, (iii) absence of high-risk features, including high white blood cell (WBC) count (≥100 9 10 9 /l for T-ALL or ≥30 9 10 9 /l for B-ALL), delayed CR1 (remission required more than 2 cycles of induction therapy), or high-risk cytogenetic abnormalities according to the National Comprehensive Cancer Network 2015 guidelines, such as hypodiploidy, a complex karyotype (5 or more chromosomal abnormalities), t(9;22) or BCR-ABL1, t(v;11q23) or KMT2A (previously termed MLL) rearrangements (Lee et al, 2010; Yan et al, 2014; Alvarnas et al, 2015) and (iv) in CR1.
With the exception of 12 cases whose records of minimal residual disease (MRD) were absent and not included (i.e., 4 HID, 5 MSD and 3 MUD cases), 348 patients were enrolled from Nanfang Hospital (n = 149), Peking University People's Hospital (n = 137) and Henan Cancer Hospital (n = 62), including 127 HID, 144 MSD and 77 MUD recipients. This study was performed in accordance with the modified Helsinki Declaration, and the protocol was approved by the respective ethical review boards. Informed consent was obtained from all donors and recipients.
HLA typing
High-resolution HLA typing was used for HLA disparities. High-resolution DNA typing for HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 were performed for all patients and donors. MSDs were related sibling donors matching ≥9/ 10 HLA, MUDs were suitably unrelated donors matching ≥9/ 10 HLA and HIDs were related donors matching 5-8/10 HLA.
Transplant opportunity and donor selection
According to our guidelines , patients generally receive allo-HSCT if they have donor availability or are MRD positive after two cycles of consolidation chemotherapy. Donor selection was as follows: if a suitable MSD was available, this donor was used, but if a suitable MSD could not be obtained, a suitably matched unrelated donor was used as an alternative. If a suitable donor was unavailable within the time frame and clinical circumstance e.g., MRD positive or a urgent need to undergo transplantation, HID transplantation was used .
Conditioning and transplantation
Previously described myeloablative conditioning regimens were used , including total body irradiation (TBI; 4Á5 Gy/day, days À5 and À4) plus cyclophosphamide (Cy; 60 mg/kg/day, days À3 and À2) and busulfan (Bu; 3Á2 mg/kg/day, days À7 to À4) plus Cy (60 mg/kg/day, days À3 and À2). All HID patients were transplanted with a combination of bone marrow (BM) and peripheral blood stem cell (PBSC) grafts, whereas all MSD and MUD patients received PBSC grafts .
Graft-versus-host disease (GVHD) prophylaxis
Ciclosporin A (CsA) and methotrexate (MTX) (on days +1, +3, and +6) were administered to patients undergoing MSD transplant for GVHD prophylaxis. CsA + MTX + anti-thymocyte globulin (ATG; Thymoglobulin; Genzyme, Cambridge, MA, USA) (total ATG dose, 7Á5 mg/kg on days À3 to À1) were administered to patients undergoing MUD transplants, and CsA + MTX + ATG (total ATG dose, 7Á5-10 mg/kg on days À4 or -3 to -1) + mycophenolate (MMF) was administered to patients undergoing HID transplants for GVHD .
Infection prophylaxis
Infection prophylaxis was performed as previously described (Liu et al, 2010; Xuan et al, 2012) . Oral sulfamethoxazole and norfloxacin were used in all cases. Acyclovir and ganciclovir was given for the prophylaxis and treatment of cytomegalovirus (CMV) infection. Anti-CD20 antibody (rituximab, 375 mg/m 2 ) was pre-emptively administered for Epstein-Barr virus (EBV)-DNA viraemia or EBV-associated post-transplant lymphoproliferative disease (PTLD). Antifungal agents were used for fungal infection prophylaxis.
Preemptive therapeutic donor lymphocyte infusion (DLI)
Bone marrow samples were analysed before transplantation, at 1, 2, 3, 4Á5, 6, 9 and 12 months after transplantation, and at 6-month intervals thereafter to monitor for MRD as previously reported . To prevent relapse , pre-emptive therapeutic DLI was administered to patients who met the following criteria: tumor gene 1 (WT1) or both in a single sample, (iii) no development of grade II or greater acute GVHD (aGVHD) and (iv) donor lymphocytes were available. Donor lymphocytes were obtained from original donors. Collections were performed on the fifth day of mobilization with granulocyte colony-stimulating factor, and consecutive daily collections were performed until the target numbers of stem cells planned for transplantation and DLI were acquired. Donor lymphocytes were cryopreserved separately for DLI. DLI was given monthly until GVHD occurred or MRD became negative, or a total of 4 times. Once patients developed GVHD after DLI, DLI was discontinued .
Evaluation points and definitions
This study mainly focused on engraftment, GVHD, relapse, transplant-related mortality (TRM), overall survival (OS), disease-free survival (DFS), and GVHD-free, relapse-free survival (GRFS). TRM was estimated as death without evidence of leukaemia recurrence. DFS was defined as survival in continuous complete remission without haematological relapse. GRFS events were defined as grades 3-4 aGVHD, chronic GVHD (cGVHD) requiring systemic immunosuppressive treatment, leukaemia relapse, or death from any cause during follow-up after allo-HSCT (Holtan et al, 2015) . aGVHD and cGVHD were graded according to the literature (Przepiorka et al, 1995) .
Statistical analysis
Analysis was performed on 23 March 2016. Patient-and transplant-related variables of the patients were described using number and percentage for categorical variables, or median and range for continuous variables. Variables considered were: recipient age, sex of the recipient and donor, disease characteristics (lineage, MRD+ at pre-transplant). Transplant characteristics included type of donor, conditioning with Bu or TBI, mononuclear cell (MNC) cell yield, and intervention of post-transplantation pre-emptive DLI. Probabilities of survival, OS, DFS and GRFS were calculated using the Kaplan-Meier estimate. Considering the competing risks of death and relapse, cumulative incidence curves in a competing risks setting were used to calculate probabilities of aGVHD and cGVHD. Groups were then compared using the Gray test (Gooley et al, 1999) . They were also used for relapse and TRM, because death and relapse were competing events.
The Cox proportional hazards model was used to evaluate the associations of patient and transplant characteristics with outcomes in multivariate analysis. GVHD and MRD at posttransplantation were modelled as time-dependent variable to investigate the impact of these variables on the occurrence of relapse and OS with consideration of additional risk factors. Factors that were associated with survival or relapse with P-values less than 0Á10 in univariate analysis (MRD at preor post-transplantation, DLI) or factors (age, sex, donor type, GVHD) known to influence outcome were included in the final models.
The chi-square test was used to compare groups for non time-to-event categorical variables. All P values were twosided with the significance level fixed at 0Á05. SPSS 19.0 (SPSS Inc., Chicago, IL, USA) and R version 3.3.0 (R Development Core Team, Vienna, Austria) were used for all data analysis.
Results
Patient and transplant donor characteristics
The characteristics of the patients and transplant donors in this study are summarized in Table I . The median age of the groups was significantly different (P = 0Á012), but the proportion of teenage (aged < 20 years) patients was 18Á1%, 14Á6% and 17Á5% for the HID, MSD and MUD groups, respectively (P = 0Á669). More HID recipients underwent BuCy conditioning regimens than MSD and MUD recipients (P < 0Á001). More HID recipients were MRD+ at pre-transplantation compared with MSD group (22Á8% vs.11Á8%, P = 0Á016); however, the HID and MUD, and MSD and MUD groups were not significantly different (P = 0Á116, 0Á648, respectively). The baseline for other factors was equivalent, including patient gender, donor gender, immune type, and the number of MNC in the graft (P > 0Á05).
Engraftment
The median time of neutrophil engraftment was 13 days (range: 9-54 days) for the HID group, which was later than the 12 days for both the MSD group (range: 8-43 days) and the MUD group (range: 10-52 days) (P = 0Á007 and 0Á006 respectively). The median time of platelet engraftment for the HID group was 15 days (range: 9-90 days), which was later than the 13 days for the MSD group (range: 9-62 days, P = 0Á001) but not statistically different from the MUD group at 14 days (range: 10-69 days, P = 0Á055). Chimerism analysis demonstrated that all patients had complete donor chimerism at day 30 post-transplantation.
Preemptive therapeutic DLI and GVHD
MRD positivity was observed in 60 patients after transplantation, including 17 HID recipients, 31 MSD recipients and 12 MUD recipients (P = 0Á190). According to our criteria, preemptive therapeutic DLI was administered to 50 patients, including 13 HID recipients (10Á2%), 27 MSD recipients (18Á8%) and 10 MUD recipients (13Á0%) (P = 0Á127). The median time for DLI was 157 days (range: 65-556 days) post-transplantation, including 189 days (range: 72-556 days), 129 days (range: 65-550 days) and 187 days (range: 70-549 days), for HID, MSD and MUD recipients, respectively (P = 0Á130), and the median number of DLI dose was 1 (range: 1-4) per patient in the 3 groups (P = 0Á917). A median donor lymphocyte dose of 2Á08 9 10 7 /kg (range 0Á64-5Á66 9 10 7 /kg) CD3 + T cells was given once. The overall cumulative incidences of grade II-IV aGVHD by day +100 post-transplantation were 40Á2% [95% confidence interval (CI) 31Á6-48Á7], 27Á1% (19Á8-34Á4) and 44Á2% (33Á0-55Á3), respectively, for the HID, MSD and MUD groups (HID versus MSD, P = 0Á025; MUD versus MSD, P = 0Á014; HID versus MUD, P = 0Á660), and the overall incidences of grade III-IV aGVHD were 12Á6% (6Á8-18Á4), 11Á8% (6Á5-17Á1) and 14Á3% (6Á4-22Á2) (P = 0Á887). After ruling out effects from DLI, the incidences of grade II-IV aGVHD by day +100 post-transplantation were 39Á5% (30Á5-48Á5), 24Á0% (16Á2-31Á8) and 40Á3% (28Á4-52Á2) for patients in the HID, MSD and MUD groups, respectively (P = 0Á020) (HID versus MSD, P = 0Á011; MUD versus MSD, P = 0Á023; HID versus MUD, P = 0Á971, Fig 1A) . However, the incidences of grade III-IV aGVHD were not significantly different among the HID, MSD and MUD groups [11Á4% (5Á5-17Á3), 7Á7% (2Á8-12Á5), 13Á5% (5Á2-21Á7), respectively, P = 0Á468, Fig 1B] .
Of the 348 study patients, 329 survived longer than 100 days, including 49 cases that received DLI. The overall 3-year cumulative incidence of cGVHD post-transplantation was 49Á5% (39Á9-59Á1), 47Á3% (38Á0-56Á6) and 48Á7% (35Á9-61Á5), respectively, for the HID, MSD and MUD groups (P = 0Á727), and that of extensive cGHVD was 19Á9% (12Á6-27Á3), 13Á8% (7Á8-19Á7) and 17Á2% (7Á7-26Á7), respectively (P = 0Á406). Excluding the patients the received DLI, the 3-year cumulative incidence of cGVHD was 45Á6% (35Á4-55Á7), 39Á6% (29Á4-49Á9) and 41Á8% (28Á2-55Á4), respectively, for the HID, MSD and MUD groups (P = 0Á467, Fig 1C) , and extensive cGHVD was not significantly different among the groups [13Á6% (6Á9-20Á2), 8Á7% (3Á2-14Á2) 8Á7% (1Á3-16Á1), respectively, P = 0Á400, Fig 1D] .
Relapse
Fifty-four patients experienced relapse at a median of 230 days (range: 45-820 days): 270 days for HID transplant recipients (range: 45-820 days), 150 days for MSD transplant recipients (range: 60-761 days) and 240 days for MUD transplant recipients (range: 60-545 days) (P = 0Á120). The 5-year cumulative incidence of relapse post-transplantation was 14Á8% (7Á9-21Á7), 21Á1% (13Á7-28Á4) and 16Á7% (7Á5-26Á0), respectively, for the HID, MSD and MUD groups (P = 0Á231, Fig 2A) . However, if both MRD-positive and morphological relapse were counted as relapse at the MRD level, the respective 5-year incidences would be 26Á0% (21Á7-30Á3), 37Á7% (33Á4-42Á0) and 31Á8% (25Á5-38Á1) (HID versus MSD, P = 0Á013; HID versus MUD, P = 0Á344; MUD versus MSD, P = 0Á199, Fig 2B) .
TRM
Seventy-nine patients died at a median of 8Á5 months (range: 1-31Á4 months) during follow-up, and the causes of death included relapse (n = 34) and TRM (n = 45). Of the 45 patients who died of TRM, infections (n = 23, including 2 EBV-associated PTLD) were the main cause of TRM, including 10 infectious diseases for HID recipients, 7 for MSD recipients and 6 for MUD recipients (P = 0Á912). Other causes included acute GVHD (n = 11, including 2 after preemptive DLI), cGVHD (n = 3, including 1 after DLI), hepatic veno-occlusive disease (n = 1), intracranial haemorrhage (n = 1), thrombotic microangiopathy (n = 1), haemorrhagic cystitis (n = 1), graft rejection (n = 1) and multiple organ failure (n = 3). The 5-year cumulative TRM rate is shown in Fig 3. There was no difference in the 5-year TRM amongst the HID, MSD and MUD groups [16Á4% (9Á6-23Á3), 11Á6% (5Á1-18Á1) and 19Á6% (9Á1-30Á0), respectively, P = 0Á162].
OS, DFS and GRFS
The cumulative incidences for OS and DFS are shown in Fig 4. No significant difference in the 5-year cumulative OS post-transplantation was identified among the HID, MSD and MUD groups [70Á1% (65Á5-74Á7), 73Á7% (69Á0-78Á4) and 69Á8% (63Á5-76Á1), respectively, P = 0Á525, Fig 4A] . Similarly, there was no statistical difference in the 5-year DFS rates amongst the HID, MSD and MUD groups [68Á7% (64Á2-73Á2), 67Á3% (62Á7-71Á9) and 63Á7% (57Á3-70Á1), respectively, P = 0Á606, Fig 4B] . Furthermore, the 1-year and 3-year GRFS was not significantly different amongst the HID, MSD and MUD groups [1-year GRFS: 57Á4% (53Á0-61Á8), 61Á4% (57Á3-65Á5) and 58Á0% (52Á2-63Á8), respectively, P = 0Á825, Fig 5A; 3-year GRFS: 50Á8% (46Á1-55Á5), 54Á9%
(50Á4-59Á4), and 52Á2% (46Á1-58Á3), respectively, P = 0Á847, Fig 5B] .
Risk factors for relapse, OS and DFS
For all patients (Table II) , pre-transplantation and posttransplantation MRD positivity were both independent risk factors of relapse [P = 0Á001 for both; hazard ratio (HR) = 2Á95 and 3Á23; 95% CI 1Á58-5Á48 and 1Á57-6Á64, respectively]. No other factors, including donor type, patient age, sex, aGVHD and cGVHD, were found significantly associated with relapse in multivariate analysis. For OS (Table II) , severe aGVHD and post-transplantation MRDpositivity were independent risk factors (P = 0Á001, <0Á001; HR = 2Á49 and 3Á75; 95% CI 1Á48-4Á17, and 2Á21-6Á68, respectively), whereas other factors demonstrated no association with OS. For DFS (Table II) , pre-and post-transplantation MRD-positivity and severe aGVHD were risk factors (P = 0Á021, <0Á001 and =0Á021; HR = 1Á75, 3Á70 and 1Á79; 95% CI 1Á09-2Á81, 2Á17-6Á30, and 1Á09-2Á93, respectively), whereas donor type, patient age, sex and cGVHD were not associated with DFS.
For patients who were MRD-positive at post-transplantation (Table III) , pre-transplantation MRD-positivity was an independent risk factor of relapse (P = 0Á012; HR = 5Á81; 95% CI 1Á47-22Á93), but pre-emptive DLI was a protective factor (P = 0Á015; HR = 0Á23; 95% CI 0Á07-0Á75), and no other factors were associated with relapse in multivariate analysis. For OS, severe aGVHD was an independent risk The cumulative incidence of aGVHD grade II-IV by day +100 post-transplantation was 39Á5%, 24Á0% and 40Á3% for the HID, MSD and MUD groups, respectively; (B) The incidence of grade III-IV aGVHD was not different among the 3 groups (11Á4%, 7Á7%, 13Á5% respectively); (C) The 3-year incidence of cGVHD was 45Á6%, 39Á6%, and 41Á8%, respectively, for the HID, MSD and MUD groups; (D) The 3-year incidence of extensive cGVHD was 13Á6%, 8Á7%, 8Á7%, respectively. aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; CI, cumulative incidence; HID, haploidentical donor; MSD, matched sibling donor; MUD, matched unrelated donor.
factor (P = 0Á003; HR = 3Á85; 95% CI 1Á56-9Á49), whereas DLI remained a protective factor (P = 0Á016; HR = 0Á29; 95% CI 0Á11-0Á80). For DFS, pre-transplantation MRD-positivity and severe aGVHD were risk factors (P = 0Á013, and =0Á013; HR = 3Á13 and 2Á83; 95% CI 1Á27-7Á71 and 1Á25-6Á40, respectively), whereas DLI was also a protective factor (P = 0Á002; HR = 0Á23; 95% CI 0Á09-0Á59). Additionally, donor type, patient age and sex were not associated with DFS.
Discussion
Over the past 30 years, adults with ALL have achieved complete remission rates of 74-93%, but long-term DFS was much lower for patients lacking a suitable donor (Goldstone et al, 2008; Cornelissen et al, 2009; Gupta et al, 2013) . Because the high incidence of relapse is a main cause for treatment failure for adult ALL, optimal post-remission therapy, particularly HSCT, is critical (Lee et al, 2010) . The majority of studies have demonstrated that adults ALL patients in CR1 may benefit from MSD and MUD, including cord blood transplantation (CBT) (Kumar et al, 2008; Tomblyn et al, 2009; Nishiwaki et al, 2013b) , particularly for high-risk patients (Yanada et al, 2006; Gupta et al, 2013; Paulson et al, 2014; Dhedin et al, 2015) . These reports also indicated that MSD transplants result in similar OS to MUD transplants, including CBT (Tomblyn et al, 2009; Nishiwaki et al, 2013b) . Our recent study has demonstrated that the outcomes for HID transplants have approached those for MSD transplants in Ph-negative, high-risk adults with ALL in CR1 , and for CBT in high-risk paediatric ALL . With regards to HID transplants for standard-risk adults with ALL CR1, Yan et al (2014) reported a 5-year cumulative OS for HID transplants of 70Á4%, with a 5-year DFS of 54Á4%, which were superior to those of chemotherapy. Mo et al (2015) reported that the 3-year OS and DFS of HID transplants were not different between standard-risk and high-risk recipients. However, few studies have compared standard-risk ALL HID transplants with HLA-matched transplants. In this study, we compared the outcomes of HID transplants with those of MSD and MUD transplants, and all of the recipients were standard-risk adults with ALL in CR1. Our results demonstrated that the cumulative 5-year OS was 70Á1%, 73Á7%, and 69Á8% and the 5-year DFS was 68Á7%, 67Á3%, and 63Á7% for the 3 respective groups, indicating that the OS and DFS of the HID transplants were not inferior to those of the MSD and MUD transplants. We also analysed GRFS, and found that the 1-year and 3-year GRFS of HID transplants was equivalent to those of the MSD and MUD transplants. A major obstacle to successful HID transplantation is the high incidence and mortality of GVHD compared with HLA- matched transplants. Increasingly, improvements have been made in prophylaxis for GVHD, such as the use of T-cell depletion in vivo by means of Cy or ATG (Bashey et al, 2013; Luo et al, 2014; Chang et al, 2016b) . Using the Cy strategy, the incidence of grade II-IV aGVHD was approximately 30%, and it was 10% for grade III-IV aGVHD for HID transplants (Bashey et al, 2013; Rubio et al, 2016) . Using another strategy, which involved T-cell replete grafts combined with ATG to result in T-cell depletion in vivo (Liu et al, 2010; Luo et al, 2014; Yu et al, 2016) , our recent randomized study demonstrated that the incidence of grade III-IV aGVHD and extensive cGVHD was only 6% and 14%, respectively, for HID transplants . In this report, although the cumulative incidence of grade II-IV aGVHD was higher for HID and MUD than MSD transplants, the incidence of grade III-IV aGVHD for HID and MUD transplants was 11Á4% and 13Á5%, respectively, which were not higher than that of MSD transplantation. Moreover, the extensive cGVHD of 13Á6% for HID transplants was also not higher than that of MSD and MUD transplants. Leukaemia relapse remains the major cause of transplant failure. Many factors influence relapse, such as underlying primary disease, disease status at transplantation, donor sources and genetics. Some reports have suggested that ALL has higher relapse rates than acute myeloid leukaemia (AML) because the graft-versus-leukaemia (GVL) effect in ALL was less effective compared with AML in allo-HSCT (Fielding et al, 2007; Ciceri et al, 2008) . However, Solomon et al (2016) reported that the relapse rate was not different between ALL and AML after allo-HSCT. It has been reported by other studies that ALL could benefit from the GVL effect by DLI intervention (Yan et al, 2012; Chen et al, 2015) , including patients with ALL relapse post-transplantation (Terwey et al, 2013; Yan et al, 2016) .
Our results demonstrate that MRD at both pre-and posttransplantation is a high-risk factor for relapse and DFS, and MRD at post-transplantation could worsen OS. Although cGVHD does not affect relapse and survival for all our patients, consistent with our recent study , pre-emptive DLI could decrease haematological relapse, improving DFS and OS of MRD positive patients post-transplantation. These results indicate that ALL could benefit from GVL. It is also debatable whether HID and MUD have a stronger GVL effect than MSD. Some studies have suggested that MUD transplants have a stronger GVL effect than MSD, but another report demonstrated that MUD transplants do not have this effect (Ringden et al, 2009) . Reports from our group and others have demonstrated that HID transplants could achieve a stronger GVL effect than MSD for acute leukaemia (Wang et al, 2011; Luo et al, 2014; Yu et al, 2016) . In this study, the 5-year incidence of haematological relapse plus MRD at post-transplantation was lower for HID than MSD, but there was no difference between HID and MUD transplants, suggesting that HID transplants might have a stronger GVL effect. In addition, although more MRD was observed in HID transplant recipients than 
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; CI, confidence interval; DFS, disease-free survival; HID, haploidentical donor; HR, hazard ratio; MRD, minimal residual disease; MSD, matched sibling donor; MUD, matched unrelated donor; OS, overall survival. MSD recipients before transplantation, the 5-year haematological relapse rates were not different among the 3 donor types, also indicating that HID transplants might have a stronger GVL effect than MSD transplants. It is a matter of concern whether there is high TRM for HID transplants. Several reports have demonstrated that the TRM rate for HID transplants was not higher than that for MSD or MUD transplants (Xiao-Jun et al, 2009; Bashey et al, 2013; Wang et al, 2016) . In contrast, in our previous report, MSD transplants had lower TRM compared with HID and MUD transplants, while the TRM was comparable for HID and MUD . TRM was affected by complex factors, including donors, conditioning, HSCT comorbidity index, grafts, GVHD prophylaxis. In this report, TRM did not differ amongst the HID, MSD and MUD groups. A reasonable interpretation for our findings compared with previous results might be that more advanced leukaemia patients underwent HID or MUD transplants with more intense conditioning in the previous report, leading to higher risk for infection (Xuan et al, 2012; Yu et al, 2016) .
In conclusion, our results suggest that the outcomes of HID transplant are equivalent to those of MSD and MUD transplants. HID transplantation might be an alternative front-line choice for standard-risk adults with ALL in CR1 who lack a matched donor.
